Published Technical Disclosure Archive

Next-Generation Cardiac Arrhythmia Treatment Systems

Publication ID: 24-11857380_0010_PTD
Published: October 28, 2025
Category:Future Evolutions & Paradigm Shifts

Legal Citation

pr1or.art Inc., “Next-Generation Cardiac Arrhythmia Treatment Systems,” Published Technical Disclosure No. 24-11857380_0010_PTD, Published October 28, 2025, available at https://archive.pr1or.art/24-11857380_0010_PTD
This technical disclosure describes improvements that would be readily apparent to a Person Having Ordinary Skill In The Art (PHOSITA) when considered in combination with the foundational architecture disclosed in U.S. Patent No. 11,857,380.

Summary of the Inventive Concept

A suite of revolutionary cardiac arrhythmia treatment devices and methods that leverage AI, machine learning, and miniaturized technologies to provide personalized, real-time, and adaptive therapy optimization.

Background and Problem Solved

The original patent addressed the need for effective cardiac arrhythmia treatment devices, but its limitations included the need for invasive lead implantation and limited real-time adaptability. The new inventive concept addresses these limitations by introducing leadless pacemakers, neural network-based algorithms, and real-time optimization capabilities.

Detailed Description of the Inventive Concept

The inventive concept comprises a subcutaneously implantable pulse generator, a leadless cardiac pacemaker disposed within a chamber of the heart, and a neural network-based algorithm for real-time cardiac rhythm analysis and personalized therapy optimization. The system can also include a machine learning-based approach for optimizing pacing parameters, a miniaturized pulse generator implantable in a patient's ear, and a swarm of micro-robots deployable in a patient's heart. These components enable real-time cardiac rhythm analysis, personalized therapy optimization, and targeted electrical stimulation therapy.

Novelty and Inventive Step

The new inventive concept introduces the use of leadless pacemakers, neural network-based algorithms, and real-time optimization capabilities, which are not present in the original patent. These advancements enable more effective, personalized, and adaptive cardiac arrhythmia treatment.

Alternative Embodiments and Variations

Alternative embodiments of the inventive concept could include the use of different types of implantable devices, such as implantable cardioverter-defibrillators or cardiac resynchronization therapy devices. Variations could also include the integration of additional sensors or data sources, such as genomic data or wearable device data, to further enhance personalized therapy optimization.

Potential Commercial Applications and Market

The inventive concept has significant commercial potential in the cardiac arrhythmia treatment market, which is projected to grow significantly in the coming years. The target industries include medical device manufacturers, healthcare providers, and pharmaceutical companies.

CPC Classifications

SectionClassGroup
A A61 A61B90/39
A A61 A61B90/02
A A61 A61N1/0504
A A61 A61N1/0563
A A61 A61N1/0587
A A61 A61N1/362
A A61 A61N1/3621
A A61 A61N1/36521
A A61 A61N1/36542
A A61 A61N1/36557
A A61 A61N1/3787
A A61 A61N1/37217
A A61 A61N1/37264
A A61 A61N1/3956
A A61 A61B2090/3966
A A61 A61B2090/3983
A A61 A61N1/059
A A61 A61N1/3752

Field of Art

Cardiac medical devices, specifically implantable cardiac rhythm management systems, involving electrical stimulation technologies, medical device design, and advanced signal processing for cardiac therapy

Person of Ordinary Skill (PHOSITA) Profile

A biomedical engineer with expertise in electrical medical devices, advanced signal processing, neural network technologies, miniaturized implantable systems, and cardiac rhythm management, holding advanced degrees in biomedical engineering or electrical engineering with specialized training in medical device design

Obviousness Rationale

A PHOSITA would recognize that the PTD's variations represent predictable technological extensions of the source patent's cardiac rhythm management framework, leveraging known machine learning and miniaturization techniques to enhance existing pacemaker technologies. The disclosed innovations represent incremental improvements using standard engineering approaches in neural network integration, device miniaturization, and personalized medical treatment optimization. These variations would be considered obvious combinations of known techniques within the cardiac medical device domain.

Obvious Combinations & Variations

Source Patent Element
Cardiac lead insertion method for electrical pulse transmission to heart
PTD Variation
Leadless cardiac pacemaker disposed directly within heart chamber
Obviousness Reasoning
Predictable design evolution eliminating external leads, representing a known miniaturization trend in implantable medical devices with expected performance improvements
Source Patent Element
Therapeutic electrical pulse generation for cardiac rhythm management
PTD Variation
Neural network-based algorithm for real-time cardiac rhythm analysis and personalized therapy optimization
Obviousness Reasoning
Application of machine learning techniques to existing pulse generation methods, representing a standard engineering approach to enhancing medical device functionality using known computational techniques
Source Patent Element
Intercostal space lead placement for cardiac therapy
PTD Variation
Miniaturized pulse generator implantable in alternative anatomical locations like patient's ear
Obviousness Reasoning
Routine design variation exploring alternative implantation sites using established medical device miniaturization principles
Source Patent Element
Electrical pulse transmission for cardiac therapy
PTD Variation
Swarm of micro-robots for targeted electrical stimulation therapy
Obviousness Reasoning
Logical technological progression utilizing emerging micro-robotic technologies to achieve more precise electrical stimulation, representing an expected innovation path for medical device engineers
35 U.S.C. § 103 Summary: Based on the teachings of US Patent 11857380 and the disclosed technological variations, a Person Having Ordinary Skill In The Art would find the claimed innovations obvious and lacking non-obvious inventive merit. The published technical disclosure demonstrates that the claimed advancements represent predictable combinations of known techniques in cardiac rhythm management, neural network integration, and medical device design, thereby rendering subsequent similar claims obvious under 35 U.S.C. Section 103.

Original Patent Information

Patent NumberUS 11,857,380
TitleCardiac arrhythmia treatment devices and delivery
Assignee(s)AtaCor Medical, Inc.